{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T17:07:20Z","timestamp":1756573640765,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,3]]},"DOI":"10.1182\/blood.2023020769","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T15:30:33Z","timestamp":1691076633000},"page":"402-404","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Karyotype and outcome in CLL"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-2098","authenticated-orcid":false,"given":"Stephen P.","family":"Mulligan","sequence":"first","affiliation":[{"name":"1Royal North Shore Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2023080315302699300_bib1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood.2023019634","article-title":"High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations","volume":"142","author":"F\u00fcrstenau","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2023080315302699300_bib2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2141.1984.tb06112.x","article-title":"Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia","volume":"58","author":"Pittman","year":"1984","journal-title":"Br J Haematol"},{"issue":"11","key":"2023080315302699300_bib3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJM199009133231105","article-title":"Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities","volume":"323","author":"Juliusson","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2023080315302699300_bib4","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2023080315302699300_bib5","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2023080315302699300_bib6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3324\/haematol.2020.274456","article-title":"Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients","volume":"107","author":"Ramos-Campoy","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"2023080315302699300_bib7","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"issue":"36","key":"2023080315302699300_bib8","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023080315302699300_bib9","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"7762","key":"2023080315302699300_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-019-1252-x","article-title":"Growth dynamics in naturally progressing chronic lymphocytic leukaemia","volume":"570","author":"Gruber","year":"2019","journal-title":"Nature"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/5\/402\/2067449\/blood_bld-2023-020769-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/5\/402\/2067449\/blood_bld-2023-020769-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T15:30:41Z","timestamp":1691076641000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/5\/402\/497140\/Karyotype-and-outcome-in-CLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,8,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020769","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2023,8,3]]}}}